ARTICLE | Clinical News
Biscayne reports Phase Ib data for epilepsy candidate BIS-001ER
November 17, 2017 7:06 PM UTC
Biscayne Neurotherapeutics Inc. (Miami, Fla.) reported data from a Phase Ib trial in 11 healthy volunteers showing that twice-daily 0.5-2.5 mg doses of epilepsy candidate BIS-001ER were well tolerated with no dose-limiting toxicities (DLTs) reported. The company also said serum exposure levels of the product were almost twice as high as the levels needed "to achieve strong efficacy results."
The primary endpoint of the open-label, Australian trial is pharmacokinetics, with a secondary endpoint of safety...
BCIQ Company Profiles
BCIQ Target Profiles